Developer docs
API playgroundTry for free, no card

Search company profiles

Aculys Pharma

Full company profile

uuid00023fo

Namestring
Aculys Pharma
Legal namestring
Aculys Pharma, Inc.
Websiteurl
aculys.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Aculys Pharma, Inc. was a Tokyo-headquartered, clinical-stage biopharmaceutical company that developed and commercialized innovative neurological and psychiatric therapies for the Japanese and broader Asia-Pacific market. Founded in January 2021 by Catalys Pacific, the company pursued a licensing-led model, in-licensing drugs already approved in the US and EU from Western developers to address Japan's documented drug lag/drug loss problem (72% of EU/US-approved drugs remained unapproved in Japan as of 2020). The company's therapeutic focus areas were refractory epilepsy, status epilepticus, narcolepsy, and obstructive sleep apnea syndrome (OSAS).

Aculys's pipeline consisted of two core assets. The first was Spydia® Nasal Spray (diazepam), an intranasal formulation licensed from Neurelis, Inc. (US), approved by Japan's MHLW in June 2025 as Japan's first intranasal anti-seizure medication and the first rescue medication approved for adults for out-of-hospital use. The second was pitolisant (BF2.649), a selective histamine H3 receptor antagonist/inverse agonist licensed from Bioprojet SCR (France) for narcolepsy and OSAS, which had received orphan drug designation and for which NDA submission was planned by end-2025. Both products received orphan drug designation from MHLW, providing priority examination (review period reduced from 12 to 9 months) and regulatory exclusivity in their designated indications.

Aculys monetized its assets through prescription pharmaceutical product sales in Japan under NHI pricing, combined with milestone payments and royalties payable under its in-licensing arrangements. Following Viatris Inc.'s completion of the acquisition in October 2025, commercialization of Spydia® transitioned to Viatris Pharmaceuticals Japan G.K., with Aculys continuing as part of the Viatris Japan Group. Total capital raised across three rounds was approximately JPY 14 billion. End-user demand was fragmented across hospital and specialty clinic prescribers (neurologists, psychiatrists, epileptologists) treating Japan's estimated 600,000-1,000,000 epilepsy patients and the underdiagnosed narcolepsy/OSAS populations, while upstream revenue concentration was anchored on the Neurelis and Bioprojet licensing partnerships.

Short descriptiontext

Aculys Pharma was a Tokyo-based clinical-stage biopharmaceutical company that in-licensed and developed innovative neurological drugs—Spydia® nasal spray for epilepsy and pitolisant for narcolepsy—for Japan and Asia-Pacific before being acquired by Viatris in October 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurology pharmaceuticals, antiepileptic drugs, nasal spray formulations, sleep disorder treatments, clinical-stage biopharmaceuticals
Industry2 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Neurology Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated from the sale of prescription pharmaceuticals. Aculys Pharma received marketing approval for Spydia® Nasal Spray (diazepam) in June 2025 and launched the product in December 2025 through Viatris Pharmaceuticals Japan.

aculys.com
2Licensing and Royalty Revenue
TypeLicensing Royalties
Description

The company held exclusive development and commercialization rights for Japan and Asia-Pacific regions for pitolisant (from Bioprojet) and diazepam nasal spray (from Neurelis). Post-acquisition by Viatris, the deal structure included upfront payment, additional contingent consideration upon regulatory and commercial milestones, and royalties on net sales.

aculys.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Spydia®
Description

Spydia® Nasal Spray - diazepam nasal spray product for treatment of status epilepticus, first intranasal anti-seizure medication approved in Japan

aculys.com
Core offering1 text field

Aculys Pharma develops and commercializes innovative prescription pharmaceuticals for neurological and psychiatric disorders in Japan and the Asia-Pacific region, focusing on drugs already approved in the US/EU to address Japan's drug lag. The company's portfolio includes Spydia® Nasal Spray (diazepam), Japan's first intranasal anti-seizure medication approved for status epilepticus, and pitolisant, a histamine H3 receptor antagonist in development for narcolepsy and obstructive sleep apnea syndrome. Both products were licensed from international partners (Neurelis and Bioprojet) and are targeted at Japanese patients with high unmet medical needs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Spydia® Nasal Spray demonstrated efficacy meeting primary endpoint in Phase 3 clinical trial with proportion of patients achieving seizure resolution within 10 minutes and remaining seizure-free for 30 minutes post-dose
+3 more records
Product overview1 text field

Aculys Pharma is a clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases. Its portfolio consists of two products: Spydia® Nasal Spray (diazepam), approved in Japan in June 2025, which is Japan's first intranasal anti-seizure medication and the first rescue treatment approved for adults outside of hospital settings; and pitolisant (BF2.649), a histamine H3 receptor antagonist/inverse agonist in late-stage development for narcolepsy and obstructive sleep apnea syndrome. Both products were sourced from international licensing partners (Neurelis for diazepam, Bioprojet for pitolisant) to address Japan's drug lag and drug loss challenges.

Product and service2 records
1Spydia® Nasal Spray (diazepam)
CategoryAntiepileptic drug / Neurology prescription pharmaceutical
Description

Japan's first intranasal anti-seizure medication, approved for the treatment of status epilepticus or seizures with potential progression to status epilepticus in patients 2 years or older. It is also the first rescue medication approved for adults for out-of-hospital use. Available in 5mg, 7.5mg, and 10mg doses. Developed by Neurelis, Inc. and commercialized in Japan and Asia-Pacific by Aculys Pharma.

2Pitolisant (BF2.649)
CategorySleep disorder prescription pharmaceutical
Description

A selective histamine H3 receptor antagonist/inverse agonist for treatment of excessive daytime sleepiness in narcolepsy (Type 1 and Type 2) and obstructive sleep apnea syndrome (OSAS). It targets the sleep-wake rhythm regulation by binding to autoreceptors in the presynaptic region of histamine-containing neurons. Approved in 38 countries globally; licensed from Paris-based Bioprojet SCR for Japan.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Viatris completed acquisition of Aculys Pharma in October 2025, gaining rights to develop and commercialize Spydia® (diazepam nasal spray) and pitolisant in Japan and Asia-Pacific regions. Deal structure included upfront payment, contingent consideration for regulatory and commercial milestones, and royalties on net sales.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-11-01
Description

Licensing agreement for exclusive development and commercialization rights in Japan and Asia-Pacific region (excluding Greater China and Singapore) for diazepam nasal spray (NRL-1). Neurelis developed the nasal spray formulation and FDA approved it as VALTOCO® in 2020 for seizure clusters in epilepsy patients 6 years and older.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-07-01
Description

Licensing agreement for exclusive development and commercialization rights in Japan for pitolisant (histamine H3 receptor antagonist/inverse agonist). Pitolisant was discovered by Paris-based Bioprojet and approved by EMA in 2016 for narcolepsy and in 2021 for OSAS, and by FDA in 2019 for narcolepsy EDS and 2020 for cataplexy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Belgian specialty pharma with a leading epilepsy franchise (Vimpat, Briviact, Fintepla). Comparable as a CNS-focused innovator with strong epilepsy commercialization capabilities; UCB's recent push into narcolepsy through the Zogenix acquisition mirrors Aculys' pitolisant play.

TypeDirect peer
Description

Specialty pharma focused on sleep disorders with Lumryz (once-nightly sodium oxybate) for narcolepsy. Comparable as a focused narcolepsy competitor with reformulation strategy in the same indication Aculys targets with pitolisant.

TypeDirect peer
Description

Specialty pharma with leading franchises in narcolepsy (Xyrem/Xywav, Sunosi) and epilepsy (Epidiolex). Directly comparable as a CNS-focused commercial-stage specialty pharma in the same narcolepsy and epilepsy indications Aculys targets with pitolisant and Spydia®.

TypeOthers
Description

US-based originator of diazepam nasal spray (Valtoco) and Aculys' licensor for Spydia®. Adjacent enabler rather than direct competitor; Neurelis is the upstream partner that grants Aculys Japan/APAC rights to the NRL-1 intranasal diazepam technology.

TypeBroad incumbent
Description

Major Japanese pharma with strong CNS/psychiatry portfolio (abilify, brexpiprazole). Comparable for Japan-domestic neurology and psychiatry commercialization, though Otsuka's franchise is broader and more mature.

6Eisai Co., Ltd.
TypeBroad incumbent
Description

Japan's leading neurology-focused major pharma with deep CNS franchise (epilepsy, dementia, neurology). Comparable as a domestic Japanese pharmaceutical operator with established neurology sales infrastructure and regulatory expertise, though at far larger scale than Aculys.

TypeBroad incumbent
Description

Japan's largest pharma with broad CNS and rare disease footprint (post-Shire). Comparable as a domestic incumbent providing the talent pipeline from which Aculys recruited leadership (e.g., former Takeda exec Hidemasa Tanigaki), and as a benchmark for Japanese CNS commercialization at scale.

8Sumitomo Pharma (formerly Sumitomo Dainippon Pharma)
TypeBroad incumbent
Description

Japanese mid-cap pharma with material CNS and psychiatry presence (latuda, growth in neurology pipeline). Directly comparable as a Japan-headquartered player addressing similar neurological and psychiatric indications, with overlapping physician call points.

9SK Biopharmaceuticals
TypeEmerging player
Description

Korean/Asian-origin CNS specialist with cenobamate (Xcopri) for epilepsy. Comparable as a smaller Asia-rooted neurology player commercializing globally, mirroring Aculys' Japan-plus-Asia-Pacific licensing model with novel epilepsy therapeutics.

TypeOthers
Description

French originator and licensor of pitolisant to Aculys. Listed as an adjacent party rather than a direct peer: Bioprojet is Aculys' upstream partner for pitolisant and an established European CNS specialty player.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aculys Pharma

Neurology Pharmaceuticalsaculys.com

Aculys Pharma was a Tokyo-based clinical-stage biopharmaceutical company that in-licensed and developed innovative neurological drugs—Spydia® nasal spray for epilepsy and pitolisant for narcolepsy—for Japan and Asia-Pacific before being acquired by Viatris in October 2025.

What Aculys Pharma does

Aculys Pharma, Inc. was a Tokyo-headquartered, clinical-stage biopharmaceutical company that developed and commercialized innovative neurological and psychiatric therapies for the Japanese and broader Asia-Pacific market. Founded in January 2021 by Catalys Pacific, the company pursued a licensing-led model, in-licensing drugs already approved in the US and EU from Western developers to address Japan's documented drug lag/drug loss problem (72% of EU/US-approved drugs remained unapproved in Japan as of 2020). The company's therapeutic focus areas were refractory epilepsy, status epilepticus, narcolepsy, and obstructive sleep apnea syndrome (OSAS).

Aculys's pipeline consisted of two core assets. The first was Spydia® Nasal Spray (diazepam), an intranasal formulation licensed from Neurelis, Inc. (US), approved by Japan's MHLW in June 2025 as Japan's first intranasal anti-seizure medication and the first rescue medication approved for adults for out-of-hospital use. The second was pitolisant (BF2.649), a selective histamine H3 receptor antagonist/inverse agonist licensed from Bioprojet SCR (France) for narcolepsy and OSAS, which had received orphan drug designation and for which NDA submission was planned by end-2025. Both products received orphan drug designation from MHLW, providing priority examination (review period reduced from 12 to 9 months) and regulatory exclusivity in their designated indications.

Aculys monetized its assets through prescription pharmaceutical product sales in Japan under NHI pricing, combined with milestone payments and royalties payable under its in-licensing arrangements. Following Viatris Inc.'s completion of the acquisition in October 2025, commercialization of Spydia® transitioned to Viatris Pharmaceuticals Japan G.K., with Aculys continuing as part of the Viatris Japan Group. Total capital raised across three rounds was approximately JPY 14 billion. End-user demand was fragmented across hospital and specialty clinic prescribers (neurologists, psychiatrists, epileptologists) treating Japan's estimated 600,000-1,000,000 epilepsy patients and the underdiagnosed narcolepsy/OSAS populations, while upstream revenue concentration was anchored on the Neurelis and Bioprojet licensing partnerships.

Aculys Pharma firmographics

Firmographics
Name
Aculys Pharma
Legal name
Aculys Pharma, Inc.
Website
https://aculys.com
Company type
Private
Founded year
2021
Operating status
Acquired
Headcount range
11–50 employees
Short description
Aculys Pharma was a Tokyo-based clinical-stage biopharmaceutical company that in-licensed and developed innovative neurological drugs—Spydia® nasal spray for epilepsy and pitolisant for narcolepsy—for Japan and Asia-Pacific before being acquired by Viatris in October 2025.
Ownership category
akta.pro rank

Aculys Pharma industry classification

Industry
Product category
Neurology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Neurology pharmaceuticals
  • Antiepileptic drugs
  • Nasal spray formulations
  • Sleep disorder treatments
  • Clinical-stage biopharmaceuticals

Where Aculys Pharma is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

Aculys Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated from the sale of prescription pharmaceuticals. Aculys Pharma received marketing approval for Spydia® Nasal Spray (diazepam) in June 2025 and launched the product in December 2025 through Viatris Pharmaceuticals Japan.
  2. Licensing and Royalty Revenue: The company held exclusive development and commercialization rights for Japan and Asia-Pacific regions for pitolisant (from Bioprojet) and diazepam nasal spray (from Neurelis). Post-acquisition by Viatris, the deal structure included upfront payment, additional contingent consideration upon regulatory and commercial milestones, and royalties on net sales.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Aculys Pharma product offering

Product offering

Core offering

Aculys Pharma develops and commercializes innovative prescription pharmaceuticals for neurological and psychiatric disorders in Japan and the Asia-Pacific region, focusing on drugs already approved in the US/EU to address Japan's drug lag. The company's portfolio includes Spydia® Nasal Spray (diazepam), Japan's first intranasal anti-seizure medication approved for status epilepticus, and pitolisant, a histamine H3 receptor antagonist in development for narcolepsy and obstructive sleep apnea syndrome. Both products were licensed from international partners (Neurelis and Bioprojet) and are targeted at Japanese patients with high unmet medical needs.

Product overview

Aculys Pharma is a clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases. Its portfolio consists of two products: Spydia® Nasal Spray (diazepam), approved in Japan in June 2025, which is Japan's first intranasal anti-seizure medication and the first rescue treatment approved for adults outside of hospital settings; and pitolisant (BF2.649), a histamine H3 receptor antagonist/inverse agonist in late-stage development for narcolepsy and obstructive sleep apnea syndrome. Both products were sourced from international licensing partners (Neurelis for diazepam, Bioprojet for pitolisant) to address Japan's drug lag and drug loss challenges.

Differentiator

Problem solved

Functional benefit

Brands

  • Spydia®: Spydia® Nasal Spray - diazepam nasal spray product for treatment of status epilepticus, first intranasal anti-seizure medication approved in Japan

Products and services

  • Spydia® Nasal Spray (diazepam) Japan's first intranasal anti-seizure medication, approved for the treatment of status epilepticus or seizures with potential progression to status epilepticus in patients 2 years or older. It is also the first rescue medication approved for adults for out-of-hospital use. Available in 5mg, 7.5mg, and 10mg doses. Developed by Neurelis, Inc. and commercialized in Japan and Asia-Pacific by Aculys Pharma.
  • Pitolisant (BF2.649) A selective histamine H3 receptor antagonist/inverse agonist for treatment of excessive daytime sleepiness in narcolepsy (Type 1 and Type 2) and obstructive sleep apnea syndrome (OSAS). It targets the sleep-wake rhythm regulation by binding to autoreceptors in the presynaptic region of histamine-containing neurons. Approved in 38 countries globally; licensed from Paris-based Bioprojet SCR for Japan.

Quantifiable outcome

  • Spydia® Nasal Spray demonstrated efficacy meeting primary endpoint in Phase 3 clinical trial with proportion of patients achieving seizure resolution within 10 minutes and remaining seizure-free for 30 minutes post-dose
  • +3 more outcomes

Companies that use Aculys Pharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Aculys Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Aculys Pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Viatris Inc.coreStrategic or Co-development Partner · 1 October 2025Viatris completed acquisition of Aculys Pharma in October 2025, gaining rights to develop and commercialize Spydia® (diazepam nasal spray) and pitolisant in Japan and Asia-Pacific regions. Deal structure included upfront payment, contingent consideration for regulatory and commercial milestones, and royalties on net sales.
  • Neurelis, Inc.coreOEM/ Whitelabel/ Licensing Partner · 1 November 2021Licensing agreement for exclusive development and commercialization rights in Japan and Asia-Pacific region (excluding Greater China and Singapore) for diazepam nasal spray (NRL-1). Neurelis developed the nasal spray formulation and FDA approved it as VALTOCO® in 2020 for seizure clusters in epilepsy patients 6 years and older.
  • Bioprojet SCRcoreOEM/ Whitelabel/ Licensing Partner · 1 July 2021Licensing agreement for exclusive development and commercialization rights in Japan for pitolisant (histamine H3 receptor antagonist/inverse agonist). Pitolisant was discovered by Paris-based Bioprojet and approved by EMA in 2016 for narcolepsy and in 2021 for OSAS, and by FDA in 2019 for narcolepsy EDS and 2020 for cataplexy.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Aculys Pharma competitors and assessment

Company assessment

Direct peers

  • UCB S.A. Belgian specialty pharma with a leading epilepsy franchise (Vimpat, Briviact, Fintepla). Comparable as a CNS-focused innovator with strong epilepsy commercialization capabilities; UCB's recent push into narcolepsy through the Zogenix acquisition mirrors Aculys' pitolisant play.
  • Avadel Pharmaceuticals: Specialty pharma focused on sleep disorders with Lumryz (once-nightly sodium oxybate) for narcolepsy. Comparable as a focused narcolepsy competitor with reformulation strategy in the same indication Aculys targets with pitolisant.
  • Jazz Pharmaceuticals: Specialty pharma with leading franchises in narcolepsy (Xyrem/Xywav, Sunosi) and epilepsy (Epidiolex). Directly comparable as a CNS-focused commercial-stage specialty pharma in the same narcolepsy and epilepsy indications Aculys targets with pitolisant and Spydia®.

Others

  • Neurelis, Inc. US-based originator of diazepam nasal spray (Valtoco) and Aculys' licensor for Spydia®. Adjacent enabler rather than direct competitor; Neurelis is the upstream partner that grants Aculys Japan/APAC rights to the NRL-1 intranasal diazepam technology.
  • Bioprojet SCR: French originator and licensor of pitolisant to Aculys. Listed as an adjacent party rather than a direct peer: Bioprojet is Aculys' upstream partner for pitolisant and an established European CNS specialty player.

Broad incumbents

  • Otsuka Pharmaceutical: Major Japanese pharma with strong CNS/psychiatry portfolio (abilify, brexpiprazole). Comparable for Japan-domestic neurology and psychiatry commercialization, though Otsuka's franchise is broader and more mature.
  • Eisai Co., Ltd. Japan's leading neurology-focused major pharma with deep CNS franchise (epilepsy, dementia, neurology). Comparable as a domestic Japanese pharmaceutical operator with established neurology sales infrastructure and regulatory expertise, though at far larger scale than Aculys.
  • Takeda Pharmaceutical: Japan's largest pharma with broad CNS and rare disease footprint (post-Shire). Comparable as a domestic incumbent providing the talent pipeline from which Aculys recruited leadership (e.g., former Takeda exec Hidemasa Tanigaki), and as a benchmark for Japanese CNS commercialization at scale.
  • Sumitomo Pharma (formerly Sumitomo Dainippon Pharma): Japanese mid-cap pharma with material CNS and psychiatry presence (latuda, growth in neurology pipeline). Directly comparable as a Japan-headquartered player addressing similar neurological and psychiatric indications, with overlapping physician call points.

Emerging players

  • SK Biopharmaceuticals: Korean/Asian-origin CNS specialist with cenobamate (Xcopri) for epilepsy. Comparable as a smaller Asia-rooted neurology player commercializing globally, mirroring Aculys' Japan-plus-Asia-Pacific licensing model with novel epilepsy therapeutics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Aculys Pharma social profiles

Digital presence

Aculys Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aculys Pharma leadership team

Management profile

Number of profiles

Profiles5 records

Aculys Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aculys Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aculys Pharma

What does Aculys Pharma do?

Aculys Pharma develops and commercializes innovative prescription pharmaceuticals for neurological and psychiatric disorders in Japan and the Asia-Pacific region, focusing on drugs already approved in the US/EU to address Japan's drug lag. The company's portfolio includes Spydia® Nasal Spray (diazepam), Japan's first intranasal anti-seizure medication approved for status epilepticus, and pitolisant, a histamine H3 receptor antagonist in development for narcolepsy and obstructive sleep apnea syndrome. Both products were licensed from international partners (Neurelis and Bioprojet) and are targeted at Japanese patients with high unmet medical needs.

Is Aculys Pharma a public or private company?

Aculys Pharma is a private company. It is classified as corporate owned and is currently acquired.

When was Aculys Pharma founded?

Aculys Pharma was founded in 2021. It employs 11 to 50 people.

Where is Aculys Pharma based?

Aculys Pharma is headquartered in Tokyo, Japan, in the Asia region.

How does Aculys Pharma make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Royalty Revenue.

Who are Aculys Pharma's main competitors?

Direct peers on record are UCB S.A., Avadel Pharmaceuticals and Jazz Pharmaceuticals. Others are Neurelis, Inc. and Bioprojet SCR. Broad incumbents are Otsuka Pharmaceutical, Eisai Co., Ltd., Takeda Pharmaceutical and Sumitomo Pharma (formerly Sumitomo Dainippon Pharma). SK Biopharmaceuticals is listed as an emerging player.

Does Aculys Pharma have an API?

No public API is recorded for Aculys Pharma.

What industry is Aculys Pharma in?

Aculys Pharma's product category is Neurology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Insider Trading & Hedge Fund DataViatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business?Japan's Ministry of Health, Labour and Welfare approved WAKIX (pitolisant) for narcolepsy and excessive daytime sleepiness in obstructive sleep apnea patients. The approval covers both indications, and Viatris holds exclusive Japanese rights from its Aculys Pharma acquisition. Pricing, launch date, and prescription uptake will determine its financial contribution.openPR.comOutlook on the Catalepsy Treatment Market: Major Segments, Strategic Developments, and Leading CompaniesThe catalepsy treatment market is projected to reach $131.22 billion by 2030, growing at a compound annual growth rate of 7.2%, driven by increased neurological disorder research, personalized medicine adoption, and expanded specialized clinic networks. In October 2025, Viatris completed the acquisition of Aculys Pharma, a specialty pharmaceutical firm focused on catalepsy treatment, to broaden its specialty portfolio and accelerate product pipeline development. The market report also details treatment segmentation by type, route of administration, and end user, alongside emerging trends in combination drug therapies and multidisciplinary care approaches.TechRoundTop MedTech Startups in JapanJapan's MedTech startup ecosystem is expanding as the country addresses its ageing population challenges through robotics, AI-driven diagnostics, and digital health solutions. The article profiles several Japanese startups including LinqMed (developing radiopharmaceuticals for cancer treatment, Phase III trials), Boston Medical Sciences (AI-powered colorectal cancer screening), Dioseve (using iPS cells for infertility treatment), 12Pharmacy (veterinary pharmacy services), Aculys Pharma (neurological drug development), and Medical Note (healthcare information platform). The sector is described as growing due to increased investment and government support, though it operates at a slower pace than Silicon Valley.PR NewswireViatris Reports Third Quarter 2025 Results and Updates 2025 Financial GuidanceViatris Inc. reported third quarter 2025 total revenues of $3.76 billion, flat year-over-year on a reported basis, with adjusted EPS of $0.67 down 11% from Q3 2024, primarily due to negative impacts from its Indore, India manufacturing facility. The company completed the acquisition of Aculys Pharma, gaining exclusive rights in Japan and certain Asia-Pacific markets for pitolisant and Spydia Nasal Spray, while also submitting an NDA for its low-dose estrogen weekly patch to the FDA.YahooViatris Inc. (VTRS) Acquires Aculys Pharma, IncViatris Inc. announced on October 15 the completion of its acquisition of Aculys Pharma, Inc., a clinical-stage biopharmaceutical company focused on innovative neurological treatments. Through this transaction, Viatris obtained rights to develop and commercialize Pitolisant and Spydia, two assets in the Central Nervous System therapy area, along with rights to Spydia Nasal Spray approved in Japan and certain Asia-Pacific regions in 2025. On the same day, Truist initiated coverage of Viatris with a Buy rating and a $15 price target.BioSpaceViatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific RegionViatris Inc. has completed the acquisition of Aculys Pharma, securing exclusive rights to develop and commercialize pitolisant in Japan and Spydia® in Japan and select Asia-Pacific markets. This transaction expands Viatris' Central Nervous System portfolio, leveraging recent positive Phase 3 trial results for pitolisant in Japanese patients and the existing approval of Spydia for status epilepticus.Aculysアキュリスファーマ、Viatrisによる買収のお知らせ – Aculys Pharma, Inc.Viatris Inc. has completed the acquisition of Aculys Pharma, Inc., a Japan-based pharmaceutical company specializing in neurological and psychiatric disorders. Under the deal terms, Viatris paid a lump sum to Aculys Pharma shareholders, with additional consideration tied to regulatory and commercial milestones plus royalties on net sales. Aculys Pharma's portfolio includes Spydia® nasal solution, approved in Japan in June 2025 for status epilepticus, and Pitolisant, for which Viatris plans to submit a Japanese approval application by end of 2025 for narcolepsy and obstructive sleep apnea.ViatrisViatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific RegionViatris Inc. has completed its acquisition of Aculys Pharma, Inc., a clinical-stage biopharmaceutical company focused on neurological conditions, gaining exclusive rights to develop and commercialize pitolisant and Spydia Nasal Spray in Japan and certain Asia-Pacific markets. Pitolisant, a histamine H3 receptor antagonist for treating narcolepsy and excessive daytime sleepiness associated with obstructive sleep apnea, recently achieved positive Phase 3 trial results in Japanese patients, with regulatory filing planned for the end of 2025. Spydia Nasal Spray was approved in Japan in June 2025 for the treatment of status epilepticus, making it the first intranasal anti-seizure medication approved in Japan for this indication.